Considering these findings, we explored targeting of the JAK1/2 and STAT3/5 proteins using specific small molecule inhibitors and combined these inhibitors with standard chemotherapy, inhibitors of cell cycle progression and oncolytic adenovirus in preclinical models of bladder cancer. The gene discussed is JAK1; the disease is urinary bladder cancer.